GLP-1 Shot Peptide Market Trends, Brand Comparison, and Product Efficacy Data Analysis
Published: July 12, 2026 20:10
Author: Kevin Suzuki
Abstract: The GLP-1 shot peptide market is projected to reach $56.7 billion by 2030 (CAGR 12.5%), driven by obesity and diabetes management. Brand comparison reveals Novo Nordisk’s Ozempic/Wegovy (semaglutide) leads with 94% efficacy in weight loss, while Eli Lilly’s Mounjaro (tirzepatide) shows superior HbA1c reduction (2.1%). Key technical advantages include once-weekly dosing; disadvantages include gastrointestinal side effects (45% incidence). Product parameters vary by purity (>98%) and stability. Certifications (FDA, EMA) are critical for legitimacy. Selection tips prioritize clinical trial data, cold-chain logistics (2-8°C), and manufacturer GMP compliance. Industry trends favor oral formulations and biosimilars.